Compare · ACN vs OPRX
ACN vs OPRX
Side-by-side comparison of Accenture plc (ACN) and OptimizeRx Corporation (OPRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACN and OPRX operate in Real Estate (Real Estate), so they compete in similar markets.
- ACN is the larger of the two at $150.14B, about 900.6x OPRX ($166.7M).
- ACN has been more active in the news (22 items in the past 4 weeks vs 2 for OPRX).
- ACN has more recent analyst coverage (25 ratings vs 12 for OPRX).
- Company
- Accenture plc
- OptimizeRx Corporation
- Price
- -
- -
- Market cap
- $150.14B
- $166.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Real Estate
- Real Estate
- Exchange
- NYSE
- NASDAQ
- IPO
- 2001
- News (4w)
- 22
- 2
- Recent ratings
- 25
- 12
Accenture plc
Accenture plc, a professional services company, provides strategy and consulting, interactive, and technology and operations services worldwide. The company also provides outsourcing services. It serves communications, media, high tech, software, and platform companies; banking, capital market, and insurance industries; and consumer goods, retail, travel services, industrial, and life science industries, as well as clients in health, public service, chemicals and natural resources, energy, and utility sectors. Accenture plc has alliance relationships with Adobe, Alibaba, Amazon Web Services, Blue Yonder, Cisco, Dell, Google, HPE, IBM RedHat, Microsoft, Oracle, Pegasystems, Salesforce, SAP, ServiceNow, VMWare, Workday, Massachusetts Institute of Technology, Institut Polytechnique de Paris, CNH Industrial, and Reactive Technologies. It has an agreement with Duke Energy Corporation for the development of a technology platform designed to measure actual baseline methane emissions from natural gas distribution systems. The company was incorporated in 2009 and is based in Dublin, Ireland.
OptimizeRx Corporation
OptimizeRx Corporation operates as a digital health company that provides communications solutions for life science companies, physicians, and patients. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, therapeutic support messages, and unbranded messages. The company also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing new eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, it operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform that allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, the company offers patient programs with treatment and affordability information, lifestyle and condition trackers, Internet device connectivity, forms, and surveys. OptimizeRx Corporation is headquartered in Rochester, Michigan.
Latest ACN
- SEC Form 10-K filed by Accenture plc
- UMass Memorial Health Announces Unified Data Platform Multi-Year Initiative, Investments in AI-Powered Innovation in Partnership with Accenture and Microsoft
- SEC Form 8-K filed by Accenture plc
- SEC Form 4 filed by Accenture plc
- Accenture Launches Forward Deployed Engineering Program with Workday to Reinvent Work for the Agentic AI Era
- Accenture Acquires Sagacity Solutions to Scale AI-Driven Customer Intelligence Across Accenture Song’s UK & Ireland Operations
- From Bank Back Offices to Power Grids, Frontier AI Labs Push Deeper Into the Enterprise
- SEC Form 4 filed by Accenture plc
- Accenture and Dell Technologies Expand Collaboration to Help Enterprises Scale Private AI and Modernize Infrastructure
- SEC Form 4 filed by Accenture plc
Latest OPRX
- Chief Business Officer D'Silva Andrew J. covered exercise/tax liability with 414 shares, decreasing direct ownership by 0.42% to 99,246 units (SEC Form 4) (withholding obligation)
- B. Riley Securities resumed coverage on OptimizeRx with a new price target
- OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath
- OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence
- OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
- Chief Business Officer D'Silva Andrew J. covered exercise/tax liability with 1,432 shares, decreasing direct ownership by 1% to 99,660 units (SEC Form 4) (withholding obligation)
- OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor
- Chief Executive Officer Silvestro Stephen L was granted 79,200 shares, increasing direct ownership by 43% to 262,751 units (SEC Form 4)
- Chief Business Officer D'Silva Andrew J. was granted 57,600 shares, increasing direct ownership by 132% to 101,092 units (SEC Form 4)
- Chief Legal & Admin Officer Odence-Ford Marion was granted 57,600 shares, increasing direct ownership by 64% to 148,007 units (SEC Form 4)